UNSPSC 51162607: Amicibone

This classification denotes an antitussive agent with the molecular formula C22H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 741ZW9MD1G, chemically known as 1-(2-(1h-azepin-1-yl)ethyl)-2-oxocyclohexane carboxylic acid, benzyl ester but more generally known as amicibone, which bears US NIH Compound Identifier 31793. European Medicines Agency schedules Amicibone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05423MIG.

UNSPSC 51162607 Amicibone, a Commodity code, represents pharmaceutical and medical products that state and local governments procure for community health and emergency response initiatives. Recent solicitations show state and local buying focused on naloxone and drug deactivation systems for overdose response programs, alongside generic pharmaceuticals and over-the-counter medications distributed through cooperative purchasing alliances. Issuing bodies include county health departments and state-administered multistate cooperative purchasing organizations that aggregate demand across participating jurisdictions. Seminole County, Florida, and the Minnesota Department of Administration's Office of State Procurement represent the mix of direct county procurement and centralized cooperative contracting vehicles that characterize activity under this code.

Geographic activity spans Florida and Minnesota, with the latter reflecting multistate participation through MMCAP (the Minnesota Multistate Cooperative Purchasing Alliance), which extends purchasing access to Oregon and other participating states. Seminole County released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county's community health building and a two-year term plus one-year renewal option; the original deadline has passed. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, a two-year initial contract term effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. Both solicitations require manufacturers and distributors to meet FDA compliance, cGMP certification, and supply-chain security standards, with vendor insurance and performance benchmarks.